World Journal of Clinical Oncology

Scope & Guideline

Exploring Innovations in Clinical Oncology

Introduction

Welcome to the World Journal of Clinical Oncology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of World Journal of Clinical Oncology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2218-4333
PublisherBAISHIDENG PUBLISHING GROUP INC
Support Open AccessNo
Country-
TypeJournal
Convergefrom 2014 to 2018 (coverage discontinued in Scopus)
AbbreviationWORLD J CLIN ONCOL / World J. Clin. Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address7041 Koll Center Parkway, Suite 160, PLEASANTON, CA 94566, UNITED STATES

Aims and Scopes

The World Journal of Clinical Oncology focuses on advancing the field of oncology through the dissemination of high-quality research that addresses various aspects of cancer diagnosis, treatment, and management. The journal emphasizes a multidisciplinary approach and aims to contribute significantly to the understanding and treatment of cancer through innovative research and clinical studies.
  1. Cancer Biomarkers and Prognostic Indicators:
    Research on cancer biomarkers is a core focus, investigating their role in predicting patient outcomes, treatment responses, and disease progression across various cancer types.
  2. Innovative Treatment Modalities:
    The journal publishes studies on new and emerging treatment strategies, including immunotherapy, targeted therapies, and combination therapies, focusing on their clinical applications and efficacy.
  3. Molecular and Genetic Insights:
    There is a significant emphasis on molecular and genetic research that explores the underlying mechanisms of cancer, including studies on genetic mutations, epigenetics, and cancer genomics.
  4. Patient-Centered Care and Quality of Life:
    The journal covers research aimed at improving patient care, addressing psychosocial aspects, quality of life, and challenges faced by cancer patients, particularly in diverse populations.
  5. Clinical Trials and Real-World Evidence:
    The journal prioritizes studies that report on clinical trials, real-world evidence, and systematic reviews that guide clinical practice and policy in oncology.
The World Journal of Clinical Oncology is witnessing a dynamic shift in research themes, with several emerging topics gaining traction in recent publications. These trends reflect the evolving landscape of oncology research and clinical practice.
  1. Immunotherapy and Novel Immune Targets:
    There is a marked increase in research focusing on immunotherapy, including the exploration of immune checkpoint inhibitors and novel immune targets, reflecting a significant paradigm shift in cancer treatment.
  2. Precision Medicine and Genomic Profiling:
    Emerging studies emphasize the role of precision medicine, particularly in tailoring treatments based on individual genetic profiles and tumor characteristics, highlighting advances in genomic technologies.
  3. Cancer Microenvironment and Metabolism:
    Research exploring the tumor microenvironment and metabolic pathways in cancer is gaining attention, as understanding these factors is crucial for developing effective therapeutic strategies.
  4. Technological Innovations in Cancer Detection:
    There is a growing trend in the utilization of advanced technologies, such as machine learning and bioinformatics, to enhance cancer detection, diagnosis, and monitoring, indicating a shift towards more data-driven approaches.
  5. Psychosocial Factors in Cancer Care:
    An increasing number of studies are addressing the psychosocial aspects of cancer care, including the impact of mental health on treatment outcomes and the importance of supportive care interventions.

Declining or Waning

While the journal continues to thrive in various areas, certain themes appear to be declining in prominence based on recent publications. This may indicate shifts in research focus or advancements in the understanding of specific topics.
  1. Traditional Chemotherapy Approaches:
    There seems to be a waning interest in traditional chemotherapy protocols as the focus shifts towards personalized medicine and targeted therapies, which are perceived as more effective and less toxic.
  2. Basic Science without Clinical Implications:
    Research that does not directly translate into clinical application appears to be less frequently published, reflecting a trend towards studies that emphasize practical outcomes and patient impact.
  3. General Cancer Epidemiology Studies:
    While epidemiological studies remain important, there is a noticeable decline in publications focusing on broad epidemiological data without specific interventions or outcomes, as the journal seems to prioritize more targeted research.

Similar Journals

Bladder Cancer

Unveiling breakthroughs in bladder cancer management.
Publisher: IOS PRESSISSN: 2352-3727Frequency: 4 issues/year

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

BREAST CANCER RESEARCH AND TREATMENT

Elevating Standards in Cancer Research
Publisher: SPRINGERISSN: 0167-6806Frequency: 18 issues/year

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Targeted Oncology

Transforming oncology with cutting-edge therapies.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

Colorectal Cancer

Connecting Researchers for a Cancer-Free Future
Publisher: TAYLOR & FRANCIS LTDISSN: 1758-194XFrequency: 4 issues/year

Colorectal Cancer is an esteemed academic journal published by Taylor & Francis Ltd, focusing on all aspects of colorectal cancer research, diagnosis, treatment, and prevention. With an ISSN of 1758-194X and an E-ISSN of 1758-1958, this journal serves as a critical platform for publishing innovative studies, clinical trials, and meta-analyses to advance the understanding of colorectal cancer. Though not yet categorized under open access, it provides valuable insights and is committed to enhancing the visibility of research contributions within the field. The journal aims to foster collaboration and communication among researchers, clinicians, and students dedicated to improving patient outcomes and exploring novel therapeutic strategies. With its rigorous editorial standards, Colorectal Cancer plays a pivotal role in shaping future research and clinical practices, making it indispensable for professionals in oncology, gastroenterology, and related fields.

Current Problems in Cancer: Case Reports

Advancing oncology through shared case insights.
Publisher: ELSEVIERISSN: 2666-6219Frequency: 2 issues/year

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

Nature Reviews Clinical Oncology

Transforming Cancer Research into Practice
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Journal of the National Comprehensive Cancer Network

Uniting Knowledge: A Premier Resource for Oncology Research and Practice
Publisher: HARBORSIDE PRESSISSN: 1540-1405Frequency: 15 issues/year

The Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.

JTO Clinical and Research Reports

Empowering Global Collaboration in Cancer and Respiratory Research
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

Translational Oncology

Connecting Science and Clinical Practice in Cancer Care
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Oncology Research and Treatment

Innovating solutions for tomorrow's cancer challenges.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.